SciELO - Scientific Electronic Library Online

 
vol.13 número2Heterotopia gástrica sob a forma de pólipo esofágicoLiver disease due to schistosoma guineensis: a review índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Jornal Português de Gastrenterologia

versão impressa ISSN 0872-8178

J Port Gastrenterol. v.13 n.2 Lisboa mar. 2006

 

Acute pancreatitis due to simvastatin

A. Murinello1, E. Pinheiro2

 

Resumo

A pancreatite causada por fármacos ocorre numa incidência de 1,4-2% dos casos de pancreatite aguda, e deve ser equacionada sempre que as causas habituais de pancreatite aguda forem excluídas. Na maioria dos casos a gravidade da pancreatite por fármacos é pequena. A pancreatite aguda induzida por estatinas tem sido reportada pouco frequentemente mas, face à existência de referências de casos de pancreatite aguda causadas pela maioria das estatinas em uso, parece razoável admitir que possa estar implicado um efeito de classe das estatinas no mecanismo fisiopatológico. O mecanismo é desconhecido, mas o uso concomitante doutros fármacos parece ser importante em alguns casos. Os autores apresentam um caso de uma doente com pancreatite relacionada com sinvastatina, aconselhando que em geral, todos os doentes com pancreatite aguda causada por estatinas deveriam abdicar definitivamente da utilização destes fármacos. Foi feita uma revisão acerca dos vários tipos de reacções adversas possíveis a fármacos, salientando-se a importância da disciplina da farmacovigilância e da documentação adequada de cada reacção, de molde a tentar-se evitar a tempo lesões causadas por fármacos. A decisão médica de utilização de qualquer fármaco deverá ser baseada na relação entre risco de prescrição de um fármaco e benefícios potenciais nos doentes, considerados individualmente.

 

Summary

The incidence of drug-induced pancreatitis represents 1.4-2% of all cases of acute pancreatitis, and should be considered whenever the usual causes of acute pancreatitis are excluded. The severity of drug-induced pancreatitis is low in the majority of cases. Statin induced pancreatitis has been reported rarely, but as there have been reports of cases of acute pancreatitis caused by most of the statins in medical use, the possibility of a statin class effect being implicated in the physiopathological mechanism seems reasonable. The mechanism is unknown, but the concomitant use of another drug appears to be important in some cases. The authors present a case of a probable/likely acute pancreatitis due to simvastatin, and recommend that in general, all patients with statin induced acute pancreatitis should discontinue the use of statins permanently. A review of the several types of adverse drug reactions is presented, together with comments on the importance of pharmacovigilance and accurate documentation of these reactions, so that injury can be prevented in time. The medical decision to use a particular drug must consider the risks of prescribing the drug against the potential benefits for each individual patients.

 

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

Bibliografia

1. McArthur, KE. Review article: Drug-induced pancreatitis. Aliment Pharmacol & Therap 1996; 10: 23-8.        [ Links ]

2. Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical revue. Gastroenterol 1980; 78: 813-20.

3. Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. GUT 1995; 37: 565-7.

Março/Abril 2006 ACUTE PANCREATITIS DUE TO SIMVASTATIN 95 4. Bank L, Wright JP. 6-Mercaptopurine-related pancreatitis in 2 patients with inflammatory bowel disease. Dig Dis Sci 1984; 29:357-9.

5. Seidlin M, Lambert JS, Dolin R, Valentine FT. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS 1997; 6: 831-5.

6. Roblin X, Becot F, Jacquet J, Nairf A, Alinader J, Monet D. Pancreatite aigue sous azathioprine. (French) Ann Gastroenterol Hepatol 1990; 26: 233.

7. Moyle G, Nelson M, Hawkins D, Gazzard B. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). QJM 1993; 155-63.

8. Stevinkel P, Alvestrand A. Loop diuretic induced pancreatitis with rechallenge in a patient with malignant hypertension and renal insufficiency. Acta Med Scand 1988; 224: 89-91.

9. Eckauser M, Dakler M, Imbembo A. Diuretic-associated pancreatitis: a collective review and illustrative cases. Am J Gastroenterol 1987; 82: 865-70.

10. Belaiche G, Ley G, Slama JL. Acute pancreatitis associated with atorvastatin therapy. Gastroenterol Clin Biol 2000; 24: 471-2.

11. Lons T, Chousterman M. La simvastatine: une nouvelle molecule responsible de pancréatite aigue? (French) Gastroenterol Clin Biol 1991; 15: 93-4.

12. SinghnS, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statinb induced pancreatitis a class effect? JOP: J Pancreas (Online) 2004; 5: 502-4

13. Pluhar W. A case of possible lovastatin-induced pancreatitis in concomitant Gilbert syndrome. Wien Klin Wochenschr 1989; 101:551-4.

14. Tysk C, Al-Eryani AY, Shawabkek. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol 2002; 35: 406-8.

15. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. JOP. J Pancreas (Online) 2003; 4: 129-32.

16. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy . South Med J 1998; 91: 202-5.

17. Miltiadous G, Anthopoulon A, Elisaf M. Acute pancreatitis possibly associated with combined salycilate and atorvastatin therapy. JOP. J Pancreas (Online) 2003; 4: 20-1.

18. McDonald KB, Garber BG, Perreault MM. Pancreatitis associated with simvastatin plus fenofibrate. Ann Pharmacother 2002; 36:275-9.

19. Abdul-Ghaffar NNV, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol 1995; 21: 340-1.

20. Ramdani M, Schmidt AM, Liantard J, Duhamel O, Legroux P, Gislon J, et al. Simvastatin-induced acute pancreatitis: two cases. Gastroenterol Clin Biol 1991; 15: 986.

21. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. London: European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit;1995. Accessed at www.emea.en.int/pdfs/human/ich/037795en.pdf on 16 December 2003.

22. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.

23. Michel DJ, Knodel LC. Comparison of the algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986; 43: 1709-14

24. Naranjo CA, Busto U, Sellers EM, Sandos P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.

25. Nebeker JR, Barcel P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation and reporting. Ann Intern Med 2004; 140: 795-801.

26. Draganov P, Forsmark CE. "Idiopathic" pancreatitis. Gastroenterology 2005; 128: 756-63.

 

 

Recebido para publicação: 26/09/2005

Aceite para publicação: 15/02/2006

 

 

(1) Division of Internal Medicine 1.

(2) Division of Pharmacy.

Hospital de Curry Cabral, Lisbon, Portugal.